Fulgent Genetic (NASDAQ: FLGT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
16.8% of Fulgent Genetic shares are held by institutional investors. Comparatively, 61.0% of Harvard Bioscience shares are held by institutional investors. 9.8% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Fulgent Genetic and Harvard Bioscience’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Fulgent Genetic||$20.81 million||4.41||$2.17 million||($0.38)||-13.61|
|Harvard Bioscience||$100.79 million||1.12||$3.21 million||($0.13)||-25.00|
Harvard Bioscience has higher revenue and earnings than Fulgent Genetic. Harvard Bioscience is trading at a lower price-to-earnings ratio than Fulgent Genetic, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Fulgent Genetic and Harvard Bioscience, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fulgent Genetic currently has a consensus price target of $10.67, indicating a potential upside of 106.32%. Harvard Bioscience has a consensus price target of $5.75, indicating a potential upside of 76.92%. Given Fulgent Genetic’s higher possible upside, equities analysts clearly believe Fulgent Genetic is more favorable than Harvard Bioscience.
This table compares Fulgent Genetic and Harvard Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Harvard Bioscience beats Fulgent Genetic on 7 of the 11 factors compared between the two stocks.
About Fulgent Genetic
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
About Harvard Bioscience
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.